Loading
A phase 3 trial in lung cancer, run by Instituto Nacional de Cancerologia de Mexico, now recruiting.
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC is a phase 3, randomised interventional study registered as NCT05852990 by Instituto Nacional de Cancerologia de Mexico, with a registry enrolment figure of 28 participants, started 2022-03-01 and due to reach its primary completion in 2026-12-01. Interventions recorded: Glutamine plus L. reuteri. Conditions listed: Non-Small Cell Lung Cancer With EGFR Mutation. Primary outcome: Diarrhea toxicity; Functional Assessment of Chronic Illness Therapy. Lung eligibility wording from the registry: "* Pathologically confirmed diagnosis of NSCLC". Sites: Mexico. No results are recorded here; the registry entry is the source.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares EGFR-mutated non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.